IMRIS, Deerfield Imaging Receives FDA Clearance for the InVision™ 1.5 Surgical Theatre
IMRIS has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the new InVision 1.5 Surgical Theatre.
“We’re excited to receive regulatory clearance for commercialization of our InVision 1.5 Surgical Theatre,” said IMRIS CEO Marc Buntaine. “IMRIS continues to innovate and provide intraoperative imaging solutions that support the clinical needs of hospitals and doctors that treat neurological disorders. This new InVision system further expands and complements the IMRIS product portfolio by offering the latest innovations in 1.5T MRI.”
IMRIS custom designs innovative intraoperative MRI systems specifically for imaging during neurosurgical procedures. An IMRIS InVision Surgical Theatre helps deliver timely information to clinicians, providing real-time visualization to assist in decision-making and enhance precision in treatment.
About IMRIS, Deerfield Imaging
As a leader in image guidance solutions, IMRIS, Deerfield Imaging provides optimized, fully integrated image-guided therapy environments that address the important needs of patients, clinicians, and hospitals by delivering timely MRI and imaging data to clinicians for use during surgical or interventional procedures. The IMRIS Surgical Theatre enables intraoperative imaging directly within operating rooms. The Company also designs and manufactures proprietary head fixation devices, imaging coils and OR tables for use in this unique and multifunctional intraoperative environment. IMRIS products are sold globally to clinical centers in the neurosurgical, spinal, cardiovascular and orthopedic markets. Over 70,000 patients have benefited from lifesaving or life-extending procedures performed in an IMRIS Surgical Theatre in the past 17 years. Additional information about IMRIS, Deerfield Imaging is available at www.imris.com.
Alan Weinberg
IMRIS, Deerfield Imaging
aweinberg@imris.com
Visit us on social media:
LinkedIn
Facebook
Twitter
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
